戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  well as the only case that was treated with botulinum toxin A.
2 ridgewater, NJ) and periocular injections of botulinum toxin A.
3 or when vesicular release was inhibited with botulinum toxin A.
4 roposal as third line for strong opioids and botulinum toxin A.
5  adverse events associated with injection of botulinum toxin A.
6  light chain, the metalloprotease domain, of botulinum toxin A.
7 -) mice in response to muscle unloading with botulinum toxin A.
8 fficacy and safety of one-time injections of botulinum toxin A (200 to 240 units) in 126 subjects wit
9 nts were randomized to receive intralesional botulinum toxin A (5 U per 1 cm2) or equivalent volumes
10 ivator forskolin is blocked completely after Botulinum toxin A action.
11 ghly concentrated, unlicensed preparation of botulinum toxin A and may have received doses 2857 times
12 as no significant association between use of botulinum toxin A and reduction in the number of episodi
13  enterotoxins A and B, cholera toxin, ricin, botulinum toxin A, and heat labile toxin of E. coli).
14 staphylococcal enterotoxin A, cholera toxin, botulinum toxin A, and ricin in model buffer (PBS-BSA) a
15 ococcal enterotoxins A and B, cholera toxin, botulinum toxin A, and ricin increased 2- to 5-fold, whi
16 tidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for lidocaine patche
17                           Topical agents and botulinum toxin A are recommended for peripheral neuropa
18                                              Botulinum toxin A (Botox) is commonly used for strabismu
19                                              Botulinum toxin A (BT) is used therapeutically for the t
20 ical trial to compare topical diltiazem with botulinum toxin A (BTA) in the treatment of chronic anal
21                                              Botulinum toxin A (BTA) injection is a well-established,
22                         We hypothesized that botulinum toxin A (BTA) would prolong analgesia after sy
23 bjects were pretreated, subcutaneously, with botulinum toxin A (BTX-A) to inhibit the release of neur
24                    A unilateral injection of botulinum toxin A (BTxA) in the calf induces paralysis a
25  demonstrate that clinical use of unlicensed botulinum toxin A can result in severe, life-threatening
26                                              Botulinum toxin A compared with placebo was associated w
27 ion of the light chains of tetanus toxin and botulinum toxin A did not disrupt the restricted motion
28 oteins play a role in short-term plasticity, Botulinum toxins A, E, and F, were used to disrupt SNARE
29  to 65 years into 4 arms receiving different botulinum toxin A formulations on day 0 and with follow-
30                                     Multiple botulinum toxin A formulations were approved by the US F
31                        Subjects who received botulinum toxin A had greater improvement in flexor tone
32                        Subjects treated with botulinum toxin A had greater improvement in the princip
33                                              Botulinum toxin A-induced muscle paralysis caused pronou
34   A 3-year-old boy with esotropia received a botulinum toxin A injection into the left medial rectus
35                                   Subsequent botulinum toxin A injections allowed spontaneous eyelid
36 d limb use by the intramuscular injection of botulinum toxin A into selected forelimb muscles to prod
37 oaded pocketed microneedle device to deliver botulinum toxin A into the human dermis with the aim of
38 ar chemodenervation agents (alcohol, phenol, botulinum toxin A), intrathecally administered drugs (ba
39                                     Although botulinum toxin A is available by prescription for cosme
40                                              Botulinum toxin A is the most commonly used treatment fo
41                                              Botulinum toxin A is US Food and Drug Administration app
42 by treating organotypic cultures of SCN with botulinum toxin A or dynasore to block exocytosis and en
43                  Intramuscular injections of botulinum toxin A reduce spasticity of the wrist and fin
44 shown that proteolytic cleavage of SNAP25 by botulinum toxin A reduces the ability of Gbetagamma to c
45                Intrasphincteric injection of botulinum toxin A represents a novel technique to treat
46 rmed at P7 for WT, cKO, and muscle-unloaded (botulinum toxin A treated) attachments for quantitative
47                       Compared with placebo, botulinum toxin A was associated with a greater frequenc
48                                              Botulinum toxin A was associated with fewer chronic tens
49               Pooled analyses suggested that botulinum toxin A was associated with fewer headaches pe
50                            In single trials, botulinum toxin A was not associated with fewer migraine
51       Randomized controlled trials comparing botulinum toxin A with placebo or other interventions fo